Taysha Gene Therapies, Inc. Debt Instrument, Interest Rate, Stated Percentage
Taysha Gene Therapies, Inc. (TSHA) had Debt Instrument, Interest Rate, Stated Percentage of 11.25% as of 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentInterestRateStatedPercentage · last filed 2024-08-12
- 2022-12-31: Debt Instrument, Interest Rate, Stated Percentage 11.25%.
- 2021-08-12: Debt Instrument, Interest Rate, Stated Percentage 7.00%.
| Period end | Debt Instrument, Interest Rate, Stated Percentage |
|---|---|
| 2022-12-31 | 11.25% 10-K · filed 2023-03-28 |
| 2021-08-12 | 7.00% 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |